Skip to content
← Back to this collection

PUBLICATIONS · 35658525

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 Jan 20
First author
Wang M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Wang M
      type
      Author
    2. name
      Munoz J
      type
      Author
    3. name
      Goy A
      type
      Author
    4. name
      Locke FL
      type
      Author
    5. name
      Jacobson CA
      type
      Author
    6. name
      Hill BT
      type
      Author
    7. name
      Timmerman JM
      type
      Author
    8. name
      Holmes H
      type
      Author
    9. name
      Jaglowski S
      type
      Author
    10. name
      Flinn IW
      type
      Author
    11. name
      McSweeney PA
      type
      Author
    12. name
      Miklos DB
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Wang M
      type
      Author
    2. name
      Munoz J
      type
      Author
    3. name
      Goy A
      type
      Author
    4. name
      Locke FL
      type
      Author
    5. name
      Jacobson CA
      type
      Author
    6. name
      Hill BT
      type
      Author
    7. name
      Timmerman JM
      type
      Author
    8. name
      Holmes H
      type
      Author
    9. name
      Jaglowski S
      type
      Author
    10. name
      Flinn IW
      type
      Author
    11. name
      McSweeney PA
      type
      Author
    12. name
      Miklos DB
      type
      Author
    bibliography ids
    1. nci-bib-63ae8c396e8ecd981ddd28b0
    book metadata
    content sha256
    def9b32d2186e30af15909a483af0e78b236b971132e2feec6e8e04226ec7f1a
    document type
    citation
    dois
    1. 10.1200/JCO.21.02370
    electronic publication date
    display
    2022 Jun 4
    precision
    day
    year
    2022
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:35658525
    immutable id
    pubmed:35658525@def9b32d2186e30af15909a483af0e78b236b971132e2feec6e8e04226ec7f1a
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    3
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    555-567
    volume
    41
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      35658525
      provenance
      batch id
      9d150d55960e0c12aada
      provider
      NCBI PubMed ESummary
      record sha256
      d5f9b14dc77b062c195faaf26f847fe4c6160c0476dc938dbdf57c0e7f75fa91
      response sha256
      2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
      retrieved at
      2026-09-09T23:48:09.820498+00:00
      publication date
      display
      2023 Jan 20
      precision
      day
      year
      2023
      publication types
      1. Journal Article
      2. Research Support, N.I.H., Extramural
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/35658525/
      title
      Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

      Preserved source evidence · Not medical advice